Zhengwei Lin

Zhengwei Lin has a diverse work experience in various roles and industries. Zhengwei currently serves as the Senior Director of Global Business Development at Transcenta, where they started in 2022. Prior to this role, they worked as the Director of Global Business Development at the same company from 2020 to 2022.

Before joining Transcenta, Zhengwei was an Advisor at UCSF Health Hub starting in 2018. In 2020, they worked as a Technology Licensing Manager at City of Hope. Additionally, they served as an Independent Consultant at Valo for a brief period in 2020.

From 2019 to 2020, Zhengwei worked as a Portfolio Manager at the Consortium for Technology & Innovation in Pediatrics. Prior to that, they held two roles at the University of Southern California - Marshall School of Business. From 2019 to 2020, they were a Fund Manager at Babcock California Fund, and from 2018 to 2020, they worked as a Venture Analyst at USC Marshall Venture Fund.

In 2019, Zhengwei had a summer internship at AbbVie, where they focused on Market Access, Pricing, and Contracts. From 2015 to 2018, they worked at Fortune Ventures, first as an Investment Associate and then as a Senior Investment Associate. During their time at Fortune Ventures, they played a crucial role in investment mapping, sourcing and assessing healthcare start-ups, and leading pre-clinical drug investments.

Zhengwei has also served as a Board Member in two companies. From 2017 to 2018, they were on the board of OPM Biosciences, where they led a series A investment. From 2016 to 2018, they served on the board of Wuhan BBT CO., where they also led a series A investment. Wuhan BBT CO. is a new drug development company focused on solid tumors.

Overall, Zhengwei Lin has demonstrated expertise in business development, investment analysis, and board leadership across various sectors, including healthcare, biotechnology, and venture capital.

Zhengwei Lin's education history begins in 2005 when they earned a Bachelor of Science degree in Biotechnology from Central South University. They then pursued their passion for Oncology and Cancer Biology and obtained a Doctor of Philosophy (PhD) degree from both Peking Union Medical College and Tsinghua University. This achievement occurred between 2009 and 2014. In 2018, Zhengwei Lin further expanded their knowledge by attending the University of Southern California, where they completed a Master of Business Administration (MBA) degree with a focus on Business Administration, Management, and Operations.